Tesnatilimab, formerly known through JNJ-64304500 and currently referenced by IPH-23XX, represents a important development in the space of immuno-oncology. This antibody, a humanized IgG4 monoclonal agent, selectively targets CD40L, a key protein involved in body's activation. The current clinical studies concentrate on determining its capacity … Read More

Bococizumab has become a promising novel monoclonal antibody designed to target and inhibit the activity of proprotein. This targeted approach intends to lower levels of bad cholesterol in patients with hypercholesterolemia, a condition characterized by elevated blood cholesterol. By blocking the action of PCSK9, bococizumab suppresses the degra… Read More